| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Biowatch Alert: Oxigene Gains On 10x Volume
Posted on 04/23/2007 11:07:45 | Link | Post Comment
by H.S. Ayoub
BioHealthInvestor.com
Shares of Oxigene, Inc. (OXGN) gained more than 7% on Friday as volume was more than ten times the 3 month daily average!
There were no significant news releases or other significant events that could be detected. However, the company is expected to hold its first quarter earning conference call on Wednesday the 25th.
Oxigene focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment.
The company has a tiny market cap of only $131 million. It has over $45 million in cash and no debt according to the latest Yahoo! financial data. The company has not registered any significant revenues from operations over the last couple of years, as it has focused mostly on clinical development and research. Company insiders have been buying shares on a regular basis since 2005.
Shares of Oxigene closed at $4.66 on Friday, about 20% off the 52-week high of $5.88.
Oxigene has made BHI's BioWatch Alert List, and will be tracked for the next two weeks.
Source: BioHealthInvestor.com
_____________________
BioHealthInvestor.com
Shares of Oxigene, Inc. (OXGN) gained more than 7% on Friday as volume was more than ten times the 3 month daily average!
There were no significant news releases or other significant events that could be detected. However, the company is expected to hold its first quarter earning conference call on Wednesday the 25th.
Oxigene focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment.
The company has a tiny market cap of only $131 million. It has over $45 million in cash and no debt according to the latest Yahoo! financial data. The company has not registered any significant revenues from operations over the last couple of years, as it has focused mostly on clinical development and research. Company insiders have been buying shares on a regular basis since 2005.
Shares of Oxigene closed at $4.66 on Friday, about 20% off the 52-week high of $5.88.
Oxigene has made BHI's BioWatch Alert List, and will be tracked for the next two weeks.
Source: BioHealthInvestor.com
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Tue Jul 15, 2008 08:25AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
Morpheus Trading - Mon Jul 14, 2008 02:18AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home